Until recently, few prospective data existed to indicate safety/efficacy of NVP with entry CD4 count restricted to <250 (women) or <400 (men) cells/mm 3 . Two phase IV trials, ARTEN and NEWART, compared virologic safety/ efficacy of NVP vs ATV/r on a background of TDF/FTC in HIV+ patients within these CD4 ranges. NEWART (US) was designed to be confirmatory of ARTEN and to supplement ARTEN data [1].
Purpose of study
Until recently, few prospective data existed to indicate safety/efficacy of NVP with entry CD4 count restricted to <250 (women) or <400 (men) cells/mm 3 . Two phase IV trials, ARTEN and NEWART, compared virologic safety/ efficacy of NVP vs ATV/r on a background of TDF/FTC in HIV+ patients within these CD4 ranges. NEWART (US) was designed to be confirmatory of ARTEN and to supplement ARTEN data [1] .
Methods
In NEWART, treatment naïve patients were randomized to open-label NVP 200mg BID (lead-in dose 200mg QD x 14 days) or ATV/r (300/100mg) plus TDF/FTC (300/ 200mg). Women had CD4 counts (cells/mm 3 ) <250; men <400. Primary endpoint was virologic response prior to and at week 48 defined as confirmed HIV viral load (VL) <50 copies/mL without subsequent rebound or therapy change. A point estimate of -6.5% or higher for difference in proportion of responders (NVP-ATV/r) was considered consistent with a successful ARTEN study.
Summary of results
152 patients were treated: 89% male, 68% White, 31% Black. At baseline, mean log 10 VL was 4.9 and median CD4 count (cells/mm 3 ) was 176 (NVP) and 193 (ATV/r). Table 1 
Conclusions
NVP + TDF/FTC was noninferior to ATV/r + TDF/ FTC. Although trial discontinuations were greater in the NVP arm, VR was similar because of less documented VF. HDLc increased and TC/HDLc decreased significantly more for NVP than for ATV/r.
